AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh; Ibrahim Halil Sahin, MD
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh; Ibrahim Halil Sahin, MD
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh; Ibrahim Halil Sahin, MD
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.